Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Esophageal Neoplasms 3Sarcoma 2Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Cancer 1Sarcoma, Synovial 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Metastatic Gastric Adenocarcinoma 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Liver Neoplasms 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Renal Cell 1Carcinoma 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Ramucirumab × Clear all
NCT05894824 2025-07-11

T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Yonsei University

Phase 1/2 Recruiting
58 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT02999295 2019-08-21

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

National Cancer Center, Japan

Phase 1/2 Completed
46 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡